C4 Therapeutics develops targeted protein degradation therapies that specifically eliminate disease-causing proteins, utilizing a proprietary approach to induce selective protein removal. This technology aims to address the underlying causes of diseases, potentially transforming treatment outcomes for patients with conditions linked to dysfunctional proteins.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases are caused by the presence of dysfunctional proteins within cells. Traditional therapeutic approaches often struggle to selectively target and eliminate these specific disease-causing proteins, leading to potential off-target effects and limited efficacy.
Solution
C4 Therapeutics is developing a new class of drugs based on targeted protein degradation (TPD). This approach selectively eliminates disease-causing proteins by harnessing the body's natural protein disposal system. C4T's technology induces the degradation of specific target proteins, addressing the underlying causes of diseases. The company utilizes its TORPEDO platform to discover and develop these novel TPD therapeutics.
Target Audience
The primary target audience includes patients with diseases caused by dysfunctional proteins, as well as healthcare providers seeking more effective and targeted treatment options.
Features
- Selective degradation of disease-causing proteins
- TORPEDO platform for identifying and optimizing degrader molecules
- Oral bioavailability for convenient drug administration
- Potential for improved efficacy and reduced off-target effects compared to traditional inhibitors
- Pipeline of drug candidates targeting oncology and other diseases